Medicaid

Georgia Medicare Hepatitis B Screening Vaccine 2026 Guide

Medicare covers Hepatitis B Virus (HBV) screening for eligible beneficiaries through the Section 1861(ddd) preventive services authority.

Brevy Care Team

· 31 min read

By Brevy Care Team

Medicare covers Hepatitis B Virus (HBV) screening for eligible beneficiaries through the Section 1861(ddd) preventive services authority. CMS established HBV screening coverage effective September 28, 2016 for high-risk asymptomatic adults consistent with the 2014 USPSTF recommendation. Coverage was expanded effective for 2024 to align with the updated 2020 USPSTF Grade B recommendation for universal HBV screening of all adults. The screening uses a three-test panel (HBsAg, anti-HBs, anti-HBc) to determine current infection, prior resolved infection, vaccine-induced immunity, or susceptibility. Separately, the HBV vaccine has long been covered under Section 1861(s)(10)(B), originally limited to high-risk adults under the Omnibus Budget Reconciliation Act of 1984 (Public Law 98-369). The Inflation Reduction Act of 2022 (Public Law 117-169) Section 11401 substantially expanded HBV vaccine coverage to all Medicare beneficiaries effective January 1, 2023, eliminating the high-risk-only limitation that had constrained access for nearly 40 years.

For Georgia Medicare beneficiaries, HBV screening and vaccination represent particularly important preventive services because HBV prevalence varies substantially across populations. HBV chronic infection prevalence is substantially elevated in Asian American populations (particularly from East Asia, Southeast Asia, and the Pacific Islands) and African immigrant populations (particularly from sub-Saharan Africa). Georgia has substantial Asian American and African immigrant communities, particularly in metro Atlanta. Many beneficiaries from these populations acquired HBV vertically (mother-to-child transmission at birth) and have chronic infection that has been clinically silent for decades. Chronic HBV is a leading cause of cirrhosis and hepatocellular carcinoma worldwide. With identification through screening, treatment with nucleos(t)ide analogue antivirals can suppress viral replication and reduce progression to advanced liver disease. With vaccination — now universally available under the IRA 2022 expansion — new HBV infection is preventable. This guide explains the statutory framework for both screening and vaccination, the three-test panel interpretation, HCPCS coding, cost-sharing under the ACA Section 4104 waiver, coordination with HBV treatment, the historic OBRA 1984 origin and IRA 2022 expansion of vaccine coverage, and the Georgia HBV care landscape including Asian American and African immigrant community health resources.

Key Takeaways

Statutory authority — screening: Section 1861(ddd) of the Social Security Act provides preventive services authority allowing CMS to add coverage for screening with USPSTF Grade A or B recommendations. HBV screening was added effective September 28, 2016 for high-risk adults and expanded for 2024 to align with 2020 USPSTF Grade B universal adult screening.
Statutory authority — vaccine: Section 1861(s)(10)(B) of the Social Security Act provides HBV vaccine coverage, originally established under OBRA 1984 (Public Law 98-369) limited to high-risk Medicare beneficiaries.
IRA 2022 Section 11401 expansion: The Inflation Reduction Act of 2022 (Public Law 117-169) Section 11401 expanded HBV vaccine coverage to all Medicare beneficiaries effective January 1, 2023, with $0 cost-sharing. This eliminated the high-risk-only limitation that had constrained access since 1984.
Current screening eligibility: All adult Medicare beneficiaries are eligible for HBV screening under the 2024 universal alignment with 2020 USPSTF Grade B. Annual screening continues to apply for ongoing high-risk exposure.
HCPCS coding: HBV screening is billed under HCPCS G0499 (hepatitis B screening, with hepatitis B three-test panel: HBsAg, anti-HBs, anti-HBc).
Three-test panel interpretation: HBsAg positive indicates current infection. Anti-HBs positive indicates immunity (vaccine-induced or post-resolved infection). Anti-HBc positive indicates past or current infection (not vaccine-induced).
ACA cost-sharing waiver: ACA Section 4104 eliminates Part B deductible and coinsurance for USPSTF Grade A and B preventive services. HBV screening is $0 for beneficiaries. HBV vaccine is $0 under the IRA Section 11401 expansion.
High-risk categories: Persons born in countries with HBV prevalence 2 percent or greater, US-born persons not vaccinated as infants with parents born in countries with HBV prevalence 8 percent or greater, HIV coinfection, injection drug use, multiple sex partners, men who have sex with men, household or sexual contacts of HBV-infected persons, healthcare and public safety workers with blood exposure risk, long-term hemodialysis, transfusion before 1992.
HBV treatment: Nucleos(t)ide analogue antivirals — primarily tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), and entecavir — suppress HBV replication. Treatment is generally long-term or lifelong. Unlike HCV, current HBV antivirals suppress but do not cure infection.
Georgia landscape: Major Georgia hepatology and infectious disease programs include Emory Hepatology, Wellstar Hepatology, Piedmont Hepatology, Augusta University Hepatology, and FQHC-based programs. Asian American community health organizations and African immigrant community health resources support culturally appropriate HBV care for affected populations particularly in metro Atlanta.

Part 1: The Statutory and Regulatory Framework

Section 1861(ddd) Authority for HBV Screening

Section 1861(ddd) of the Social Security Act provides CMS authority to add Medicare coverage for "additional preventive services" beyond those specifically enumerated in the statute. The service must be:

Reasonable and necessary for the prevention or early detection of illness or disability.
Recommended with a grade of A or B by the USPSTF.
Appropriate for individuals entitled to benefits under Part A or enrolled under Part B.

HBV screening qualifies under this framework based on the USPSTF Grade B recommendation.

2016 CMS Coverage Decision for HBV Screening

CMS established Medicare coverage for HBV screening effective September 28, 2016, consistent with the 2014 USPSTF Grade B recommendation. The 2014 USPSTF recommendation supported HBV screening for adults at high risk for infection, with specific risk categories defined.

The 2016 coverage decision established:

HBV screening using the three-test panel (HBsAg, anti-HBs, anti-HBc).
Eligibility limited to specific high-risk categories.
Annual screening for individuals with continued high-risk exposure.

2020 USPSTF Update and 2024 Universal Alignment

The USPSTF released an updated HBV screening recommendation in 2020 (with subsequent confirmations through ongoing review), expanding the screening recommendation to all adolescents and adults at increased risk for HBV with continued Grade B for high-risk adults. CMS subsequently aligned coverage with the updated framework effective for 2024.

The current HBV screening framework under Medicare:

Universal screening eligibility for adults consistent with USPSTF Grade B alignment.
Annual rescreening for ongoing high-risk exposure.
Three-test panel approach to determine infection status and immunity.

Section 1861(s)(10)(B) HBV Vaccine Coverage

Section 1861(s)(10)(B) of the Social Security Act establishes Medicare Part B coverage of HBV vaccine and administration. This coverage was originally established by Section 2334 of the Deficit Reduction Act of 1984 (better known as OBRA 1984, Public Law 98-369), signed July 18, 1984. The original coverage was limited to Medicare beneficiaries at intermediate or high risk of HBV infection — specifically:

End-stage renal disease patients.
Hemophiliacs receiving Factor VIII or IX concentrates.
Clients of institutions for the mentally handicapped.
Persons living with HBV-infected persons.
Healthcare workers with frequent blood exposure.
Other high-risk categories identified by CMS.

This high-risk-only framework remained the Medicare HBV vaccine coverage structure for nearly 40 years from 1984 through the end of 2022.

Inflation Reduction Act of 2022 Section 11401 Universal HBV Vaccine Expansion

The Inflation Reduction Act of 2022 (Public Law 117-169), signed August 16, 2022, included Section 11401 expanding Medicare Part B coverage of vaccines aligned with the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations. Section 11401 specifically applies to vaccines recommended by ACIP, with $0 cost-sharing under Medicare Part B effective January 1, 2023.

For HBV vaccine specifically, this meant:

Elimination of the high-risk-only limitation that had constrained Section 1861(s)(10)(B) coverage since 1984.
Universal HBV vaccine coverage for all Medicare beneficiaries.
$0 cost-sharing (no deductible, no coinsurance) for the vaccine and administration.
Coverage aligned with ACIP recommendations.

The 2021 ACIP universal HBV vaccination recommendation for all adults age 19 to 59 (and adults age 60 or older at increased risk, with shared clinical decision-making for adults 60+ without risk factors) drove the practical expansion. Under IRA 2022 Section 11401, Medicare beneficiaries now have access to HBV vaccination regardless of risk factor status with $0 cost-sharing.

ACA Section 4104 (Public Law 111-148) eliminates Part B deductible and coinsurance for USPSTF Grade A or B preventive services effective January 1, 2011. HBV screening received USPSTF Grade B in 2014 and continues at Grade B in the 2020 update. HBV screening is $0 for beneficiaries when furnished according to CMS coverage requirements.

42 CFR 410.64 Implementing Regulations

The implementing regulations at 42 CFR 410.64 establish Medicare coverage of "additional preventive services" added through the Section 1861(ddd) framework. HBV screening operates under this regulatory framework.

Part 2: HBV Screening Eligibility Criteria

Universal Adult Screening (2024 Alignment)

Under the 2024 universal alignment with 2020 USPSTF Grade B, all adult Medicare beneficiaries are eligible for HBV screening. This represents a substantial expansion from the original 2016 high-risk-only coverage.

High-Risk Categories

Despite the expansion to universal screening, the high-risk categories remain epidemiologically important:

Persons born in countries with HBV prevalence ≥2 percent: Includes much of East Asia, Southeast Asia, the Pacific Islands, sub-Saharan Africa, parts of Eastern Europe, Central Asia, and other regions. CDC maintains country-specific prevalence data.
US-born persons not vaccinated as infants with parents born in countries with HBV prevalence ≥8 percent: Children of immigrants from high-prevalence regions, born in the US but not vaccinated as infants, particularly when from regions where HBV prevalence is very high.
HIV infection: HIV/HBV coinfection is common given shared transmission routes.
Injection drug use (past or current).
Multiple sex partners or history of sexually transmitted infection.
Men who have sex with men.
Household or sexual contacts of HBV-infected persons.
Healthcare and public safety workers with blood or body fluid exposure risk.
Persons receiving long-term hemodialysis.
Persons with chronic liver disease of unknown cause.
Persons receiving immunosuppressive therapy.
Pregnant women (also covered separately under prenatal screening but relevant for any pregnant Medicare beneficiary).

Annual Screening for Ongoing High-Risk

Beneficiaries with continued ongoing high-risk exposure (injection drug use, HIV coinfection, ongoing exposure through occupation or relationships) are eligible for annual rescreening.

Pregnant Beneficiaries

Pregnant women are routinely tested for HBV during prenatal care, with the HBsAg test being a standard component of prenatal labs. Medicare-aged pregnant beneficiaries are uncommon but the screening pathway applies.

Part 3: HCPCS Coding and the Three-Test Panel

HCPCS G0499 — Hepatitis B Screening With Hepatitis B Three-Test Panel

HCPCS G0499 is the specific code for Medicare HBV screening. The code definition includes the three-test panel:

HBsAg (hepatitis B surface antigen).
Anti-HBs (antibody to hepatitis B surface antigen).
Anti-HBc (antibody to hepatitis B core antigen).

Three-Test Panel Interpretation

The three-test panel allows differentiation among the principal HBV infection statuses:

Susceptible (uninfected, unimmunized): All three tests negative. The beneficiary has not been infected and has not been vaccinated. Candidate for vaccination.
Vaccine-induced immunity: HBsAg negative, anti-HBs positive (titer typically ≥10 mIU/mL), anti-HBc negative. The beneficiary has been successfully vaccinated and is immune.
Past resolved infection with immunity: HBsAg negative, anti-HBs positive, anti-HBc positive. The beneficiary was infected in the past, resolved the infection, and has natural immunity.
Chronic infection: HBsAg positive (persistent for >6 months), anti-HBs negative, anti-HBc positive. The beneficiary has chronic HBV infection. Requires linkage to care.
Acute infection (early): HBsAg positive, anti-HBs negative, anti-HBc positive (specifically IgM anti-HBc in acute phase). Recent acute infection.
Isolated anti-HBc (less common pattern): HBsAg negative, anti-HBs negative, anti-HBc positive. May reflect resolved infection with waned anti-HBs, occult chronic infection, false positive, or window period.

The three-test panel provides actionable clinical information across these scenarios.

Confirmatory and Additional Testing

For beneficiaries with chronic infection (HBsAg positive), additional testing supports clinical management:

HBeAg (hepatitis B e antigen) and anti-HBe — HBeAg-positive infection typically indicates higher viral replication; HBeAg-negative anti-HBe positive can indicate different chronic infection phases.
HBV DNA quantification — viral load assessment guides treatment decisions.
Alanine aminotransferase (ALT) and other liver function tests.
Liver fibrosis assessment — FibroScan, FIB-4, APRI score.
HCV antibody testing — given shared risk factors.
HIV testing — given shared risk factors.
Hepatitis A immunity testing — for vaccination consideration.
Hepatocellular carcinoma surveillance baseline — ultrasound, AFP.

These additional tests are covered as diagnostic tests under standard Part B (not under the NCD screening cost-sharing waiver).

Diagnostic Coding

HBV screening is typically submitted with diagnosis code Z11.59 (encounter for screening for other viral diseases). Risk-factor specific codes may also be used as appropriate.

ACA Section 4104 waives Part B deductible and coinsurance for USPSTF Grade A or B aligned preventive services. HBV screening received USPSTF Grade B in 2014 and continues at Grade B. HBV screening (G0499) is $0 for eligible Medicare beneficiaries.

Effective January 1, 2023, Inflation Reduction Act Section 11401 eliminated cost-sharing for ACIP-recommended vaccines under Medicare Part B. HBV vaccine and administration are $0 for all Medicare beneficiaries. This represents a substantial expansion from the prior high-risk-only $0 coverage and standard Part B cost-sharing for non-high-risk beneficiaries.

Pre-IRA Section 11401 Framework (Historical Context Through 2022)

Before January 1, 2023, the Medicare HBV vaccine coverage framework under Section 1861(s)(10)(B) provided:

$0 cost-sharing for beneficiaries meeting the high-risk eligibility categories.
Standard Part B cost-sharing (20 percent coinsurance after Part B deductible) for beneficiaries not in high-risk categories who chose to receive the vaccine.
Practical access barriers including the high-risk eligibility documentation requirements.

The IRA 2022 expansion eliminated these distinctions, providing universal $0 coverage.

Confirmatory and Follow-Up Testing

Confirmatory and follow-up testing for beneficiaries with HBV-positive screens is subject to standard Part B cost-sharing. This includes:

HBV viral load (HBV DNA quantification).
Hepatology consultation E/M visits.
Liver fibrosis assessment (FibroScan).
HCC surveillance imaging (semiannual ultrasound).
Additional laboratory testing.

Medicare Supplement insurance or Medicaid (for dually eligible) can reduce or eliminate these cost-sharing amounts.

HBV Treatment Coverage

HBV antiviral treatment is covered under Medicare Part D as outpatient prescription medication. Common HBV antivirals:

Tenofovir alafenamide (TAF, Vemlidy) — preferred for most patients given improved renal and bone safety profile.
Tenofovir disoproxil fumarate (TDF, Viread) — older formulation with somewhat higher renal and bone risk.
Entecavir (Baraclude) — alternative first-line.
Older agents (lamivudine, adefovir, telbivudine) — generally avoided in current practice due to resistance and other concerns.

Part D coverage typically requires prior authorization. The IRA Part D $2,000 out-of-pocket cap effective 2025 substantially reduces beneficiary cost-sharing for these long-term medications.

Part 5: HBV Disease Background

What Is Hepatitis B?

Hepatitis B is a viral infection affecting the liver caused by the hepatitis B virus (HBV), a DNA virus in the Hepadnaviridae family. HBV was identified in 1965. HBV vaccine was approved in 1981 (plasma-derived) and 1986 (recombinant). HBV is one of the most common chronic viral infections worldwide, with approximately 296 million people living with chronic HBV globally per WHO estimates.

Transmission

HBV is transmitted through blood and body fluids:

Vertical (mother-to-child) transmission — most common transmission route worldwide, particularly in high-prevalence countries where most chronic infections originate. Without vaccination of newborns and management of mothers, vertical transmission rate is approximately 70 to 90 percent when mothers have high viral load.
Horizontal transmission in childhood — common in high-prevalence settings through household contacts.
Sexual transmission — significant transmission route particularly in lower-prevalence settings.
Percutaneous transmission — injection drug use, healthcare exposures, tattoos and body piercings with unsterile equipment.
Blood transfusion before screening implementation.

HBV is approximately 100 times more infectious than HIV via percutaneous exposure.

Natural History

The natural history of HBV depends substantially on age at infection:

Infants infected via vertical transmission: Approximately 90 percent develop chronic infection.
Children age 1 to 5 infected: Approximately 30 to 50 percent develop chronic infection.
Adults infected: Less than 5 percent develop chronic infection; the majority clear the virus spontaneously.

This age-dependent chronicity rate explains the substantially higher chronic HBV prevalence in populations from regions with prevalent perinatal/childhood transmission.

Chronic HBV typically progresses through phases (immune tolerant, immune active, inactive carrier, reactivation) over decades. Approximately 15 to 40 percent of chronic HBV patients develop cirrhosis or HCC during their lifetime if untreated. The annual HCC incidence in cirrhotic HBV patients is approximately 2 to 5 percent.

Vaccination Effectiveness

HBV vaccine is highly effective. Standard three-dose schedule (0, 1, 6 months) produces protective anti-HBs titers in approximately 95 percent of healthy adult recipients. Two-dose Heplisav-B schedule (0, 1 month) was approved in 2017 and provides protective immunity faster. The vaccine is safe with excellent safety record over more than 40 years of use.

Part 6: HBV Treatment

Treatment Goals

Unlike HCV which is curable with DAA treatment, current HBV antiviral therapy is not curative but is highly effective at suppressing viral replication and reducing progression to advanced liver disease. Treatment goals include:

Suppression of HBV DNA to undetectable levels.
Normalization of ALT and other liver function tests.
Reduction or reversal of hepatic fibrosis.
Reduction in cirrhosis incidence.
Reduction in HCC incidence.
HBeAg seroconversion (in HBeAg-positive patients).
HBsAg loss / functional cure (uncommon but possible with sustained treatment).

Current First-Line Therapies

Tenofovir alafenamide (TAF, Vemlidy) — daily oral. Improved renal and bone safety vs. TDF. Generally preferred for older adults and patients with renal dysfunction.
Tenofovir disoproxil fumarate (TDF, Viread) — daily oral. Effective; concerns about renal toxicity and bone density loss in long-term use.
Entecavir (Baraclude) — daily oral. Alternative first-line. Avoid in lamivudine-experienced patients due to resistance.

Treatment Indications

Not all chronic HBV patients require treatment. Treatment is generally indicated for:

HBeAg-positive patients with elevated ALT and HBV DNA above 20,000 IU/mL.
HBeAg-negative patients with elevated ALT and HBV DNA above 2,000 IU/mL.
Cirrhosis (any detectable HBV DNA).
Decompensated cirrhosis.
HCV/HBV coinfection.
HIV/HBV coinfection.
Specific clinical situations (immunosuppression, prevention of HBV reactivation).

Patients in inactive carrier phase (HBeAg-negative with persistently normal ALT and low HBV DNA) typically do not require treatment but require periodic monitoring.

Long-Term Treatment

HBV treatment is typically long-term or lifelong because antiviral therapy suppresses but does not eradicate the virus. HBV cccDNA (covalently closed circular DNA) persists in hepatocyte nuclei as a stable reservoir, and treatment discontinuation typically results in viral rebound. Some patients with sustained virologic suppression may achieve HBsAg loss ("functional cure") that allows treatment discontinuation, but this is uncommon.

HCC Surveillance

Patients with chronic HBV are at elevated HCC risk independent of cirrhosis status, particularly:

Patients with cirrhosis.
Asian men age 40+.
Asian women age 50+.
African-born patients age 20+.
Family history of HCC.
HIV/HBV coinfection.
High HBV DNA viral load.

Semiannual liver ultrasound with or without alpha-fetoprotein is the standard HCC surveillance approach for high-risk chronic HBV patients.

Part 7: HBV Disease Burden and the Georgia Population

HBV Prevalence by Population

In the United States, HBV chronic infection prevalence varies substantially across populations:

Overall US prevalence: approximately 0.3 to 0.5 percent.
Asian Americans: approximately 3 to 5 percent overall, with substantial variation by country of origin and birth cohort. Asian Americans account for approximately 60 percent of chronic HBV infections in the US.
African immigrants (sub-Saharan Africa): approximately 5 to 10 percent depending on region of origin.
US-born non-Hispanic Black: approximately 0.7 percent.
US-born non-Hispanic White: approximately 0.2 percent.

Georgia HBV Population Context

Georgia has substantial populations with elevated HBV prevalence:

Atlanta metropolitan area has the largest Asian American population in the Southeast, with substantial Korean, Vietnamese, Chinese, Indian, and Filipino communities. The Buford Highway corridor in DeKalb and Gwinnett counties is a particular concentration.
African immigrant populations are substantial in metro Atlanta, with significant communities from Ethiopia, Nigeria, Somalia, Sudan, the Democratic Republic of Congo, and other sub-Saharan African nations.
Refugees from high-HBV-prevalence countries have been substantially resettled in Georgia particularly in Clarkston (DeKalb County) and surrounding areas.

Universal screening of Medicare beneficiaries (per the 2024 alignment) particularly benefits these populations.

Culturally Appropriate Care Considerations

HBV care in affected populations benefits from:

Linguistically appropriate care: HBV education and counseling in beneficiary's primary language.
Cultural understanding of HBV stigma: HBV carries stigma in some cultural contexts; sensitive engagement is important.
Family-based screening and vaccination: Screening identification of an index case warrants screening and vaccination of household members.
Coordination with community health organizations: Asian American and African immigrant community health organizations provide culturally appropriate education and screening.

Part 8: Coordination With AWV, IPPE, and Other Preventive Services

AWV Coordination

The Annual Wellness Visit under Section 1861(hhh) is a natural venue for HBV screening eligibility assessment and HBV vaccination discussion. The AWV health risk assessment captures medical history, family history, place of birth, and risk factors that inform HBV screening and vaccination decisions.

IPPE Coordination

The Initial Preventive Physical Examination under Section 1861(ww) includes review of medical history and risk factors. The IPPE is an appropriate venue for HBV screening referral and HBV vaccination assessment for newly enrolled Medicare beneficiaries.

Coordination With Other Preventive Services

HBV screening and vaccination coordinate with:

HCV screening (NCD 210.13).
HIV screening under USPSTF Grade A.
Hepatitis A vaccination (for patients with HBV or HCV).
Pneumococcal vaccination.
Influenza vaccination.
Tdap and shingles vaccination.

The bundled approach of multiple preventive services during AWV encounters supports comprehensive risk reduction.

Vaccination Workflow

The HBV vaccine series typically includes:

Engerix-B or Recombivax HB: Three-dose schedule (0, 1, 6 months).
Heplisav-B: Two-dose schedule (0, 1 month). Approved 2017.
PreHevbrio: Three-dose schedule.

Post-vaccination anti-HBs titer testing is typically not required for healthy adults but may be considered for healthcare workers and others with high exposure risk.

Part 9: The Georgia Hepatology and Asian American/African Immigrant Community Health Landscape

Emory Hepatology and Asian Liver Programs

Emory Healthcare operates comprehensive hepatology services and has specific Asian liver health initiatives reflecting metro Atlanta's substantial Asian American population. Emory Hepatology provides HBV treatment, HCC surveillance, and liver transplant evaluation through the Emory Transplant Center.

Wellstar Hepatology

Wellstar Health System operates hepatology and gastroenterology programs across north and west Georgia providing HBV treatment and management.

Piedmont Hepatology

Piedmont Healthcare operates hepatology programs across metro Atlanta and the Piedmont network including dedicated liver disease specialists.

Other Major Programs

Northside Hospital Hepatology, Augusta University Hepatology, Atrium Health Navicent Gastroenterology, Memorial Health Gastroenterology, and Phoebe Putney Gastroenterology provide hepatology and gastroenterology services across Georgia.

Asian American Community Health Organizations

Asian American community health organizations in metro Atlanta support culturally and linguistically appropriate HBV education and care:

Center for Pan Asian Community Services (CPACS) — Asian American health and social services.
Korean Community Service Center — Korean American community services.
Vietnamese American Community of Georgia — Vietnamese American community resources.

These organizations support HBV screening campaigns, vaccination promotion, and care coordination for Asian American Medicare beneficiaries.

African Immigrant Community Health Resources

African immigrant community health organizations in metro Atlanta and beyond:

Center for Black Women's Wellness — Black women's health including African immigrants.
Refugee Family Services — Refugee community health and social services.
African-American Health Alliance — African and African American health initiatives.

Coordination with Ryan White-funded HIV clinics also benefits the substantial HIV/HBV coinfected population in metro Atlanta.

FQHC-Based HBV Care

Federally Qualified Health Centers across Georgia provide HBV screening and integrated care for medically underserved populations including immigrant communities. FQHCs typically have multilingual staff and culturally appropriate services. 340B drug pricing reduces HBV antiviral costs for FQHC patients.

Part 10: Best Practices for Beneficiaries and Clinicians

Screen all adult Medicare beneficiaries under the 2024 universal alignment: Per the 2020 USPSTF Grade B and 2024 Medicare coverage alignment, universal HBV screening is the standard. Document prior screening status for beneficiaries and order screening for those without documented prior testing.
Use the three-test panel (G0499): The three-test panel (HBsAg, anti-HBs, anti-HBc) provides actionable clinical information across infection status and immunity scenarios, more comprehensive than HBsAg alone.
Document birthplace and ancestry: For Medicare beneficiaries born in or with parents from high-HBV-prevalence countries, document this to support clinical decision-making about screening frequency and family-based screening.
Initiate HBV vaccination for susceptible beneficiaries: All susceptible Medicare beneficiaries (HBsAg negative, anti-HBs negative, anti-HBc negative) should be offered HBV vaccination under the IRA 2022 universal coverage. $0 cost-sharing eliminates the prior financial barrier.
Refer chronic HBV patients to hepatology: Beneficiaries with chronic HBV (HBsAg positive sustained >6 months) typically benefit from hepatology evaluation for treatment decisions, HCC surveillance planning, and family/contact screening recommendations.
Initiate HCC surveillance for high-risk chronic HBV: Asian men age 40+, Asian women age 50+, African-born patients age 20+, cirrhotic patients, and others at elevated risk should undergo semiannual liver ultrasound with or without AFP.
Coordinate family and household contact screening: Identifying chronic HBV in an index patient warrants screening of household members and sexual partners with subsequent vaccination of susceptible contacts.
Test for HCV and HIV coinfection: Given shared transmission routes, patients with chronic HBV should be tested for HCV and HIV.
Address ongoing transmission risk: Counsel chronic HBV patients about preventing transmission to others (safe sex, no needle sharing, vaccination of household members).
Provide culturally appropriate education: For Asian American, African immigrant, and other affected populations, linguistically and culturally appropriate education improves engagement.
Counsel on long-term treatment: Patients starting HBV antiviral therapy should understand the long-term/lifelong treatment expectation, the suppressive (not curative) nature of current therapy, and the importance of adherence.
Monitor renal function for tenofovir-based therapy: TAF and TDF both have renal monitoring requirements. TAF has improved renal safety, particularly important for older adults with declining renal function.
Address hepatitis A immunization: Patients with HBV should be vaccinated against hepatitis A if not already immune.
Leverage GeorgiaCares SHIP and community resources: GeorgiaCares (1-866-552-4464) provides Medicare benefit counseling. Asian American and African immigrant community health organizations provide culturally appropriate HBV resources.

Part 11: Common Issues and Resolutions

The HBV screening claim was denied: HBV screening (G0499) under the 2024 universal alignment should be covered for any adult Medicare beneficiary not previously screened. If denied, verify claim coding (G0499 with appropriate diagnosis code) and consider appeal.
The beneficiary believes they were vaccinated decades ago but doesn't have documentation: Anti-HBs testing can determine current immunity. If anti-HBs is positive (≥10 mIU/mL) and anti-HBc is negative, vaccine-induced immunity is documented. If anti-HBs is negative or low titer, revaccination may be appropriate.
The beneficiary has chronic HBV but is being denied antiviral coverage: Part D plan prior authorization for HBV antivirals typically requires documentation of chronic HBV (HBsAg positive >6 months), elevated ALT or HBV DNA at threshold levels, or cirrhosis. Submit clinical documentation supporting treatment indication.
The beneficiary doesn't think they need HBV vaccination because they're "low risk": The IRA 2022 expansion eliminated the high-risk-only limitation. All Medicare beneficiaries can receive HBV vaccination with $0 cost-sharing under the universal coverage. The 2021 ACIP universal HBV vaccination recommendation for adults 19-59 (with shared decision-making for 60+) supports broad vaccination.
The beneficiary speaks limited English and needs HBV education: Linguistically appropriate education through Asian American or African immigrant community health organizations, professional interpreter services, or multilingual primary care/FQHC settings supports informed engagement.
The three-test panel returns an isolated anti-HBc pattern: HBsAg negative, anti-HBs negative, anti-HBc positive can reflect resolved infection with waned anti-HBs, occult chronic infection, or rarely a false positive. Follow-up testing including HBV DNA may be appropriate.
The beneficiary was vaccinated under the old high-risk-only framework but documentation is incomplete: Anti-HBs titer testing can confirm immunity. If immune, no additional doses needed. If titer is non-protective, a booster or revaccination series may be considered.
The beneficiary has HBV/HCV coinfection: Coordinate hepatology evaluation for both conditions. HCV treatment with DAAs proceeds with attention to potential HBV reactivation during HCV cure (treatment with HBV antivirals or close monitoring during HCV treatment).
The Medicare Advantage plan denies HBV vaccination: Medicare Advantage plans must cover the IRA-expanded vaccine benefits at least as comprehensively as Original Medicare. Cost-sharing must be $0 for ACIP-recommended vaccines per IRA 2022. Plan denials should be addressed through appeals.
The beneficiary is from a high-prevalence country and needs family-based screening: Family-based screening identifies chronic HBV across family members and supports vaccination of susceptible members. Coordinate with community health organizations and primary care.
The beneficiary has chronic HBV and is planning immunosuppressive treatment (e.g., chemotherapy): HBV reactivation is a serious risk with immunosuppression. Pre-emptive HBV antiviral therapy is typically indicated. Coordinate with hepatology and the treating specialist.
The beneficiary has chronic HBV and develops elevated ALT after years of stable disease: This may represent reactivation or transition to immune-active phase. HBV DNA and clinical evaluation determine whether treatment initiation is appropriate.
HCC surveillance is recommended but the beneficiary is concerned about cost: HCC surveillance using ultrasound (with AFP) is subject to standard Part B cost-sharing. Medicare Supplement, Medicaid (dually eligible), or 340B/FQHC pathways can reduce costs.
The beneficiary asks whether HBV cure is possible: Current HBV antivirals suppress but do not cure infection. HBsAg loss ("functional cure") is uncommon but does occur with sustained treatment in some patients. Research on HBV cure is active but no curative therapy is currently widely available.

Part 12: Worked Examples

Example 1: Fulton County Age 68 Vietnamese American Male Chronic HBV Detection Linked to Treatment

A 68-year-old Vietnamese American man living in Fulton County (Atlanta), enrolled in Original Medicare Part B for three years, immigrated to the US from Vietnam at age 25. He has never been screened for HBV and reports no specific identified risk factors but acknowledges that "hepatitis is common in Vietnam." He receives primary care at an Emory primary care practice with significant Vietnamese American patient population. The primary care provider, recognizing his country of birth as a high-HBV-prevalence region, recommends HBV screening under the 2024 universal alignment.

The HBV three-test panel (G0499) returns: HBsAg positive, anti-HBs negative, anti-HBc positive. This pattern is consistent with chronic HBV infection. Additional testing shows HBeAg negative, anti-HBe positive, HBV DNA 50,000 IU/mL, ALT 78 (mildly elevated), AFP 8 ng/mL (normal). FibroScan shows F2 fibrosis (moderate).

The patient is referred to Emory Hepatology. The hepatology team confirms chronic HBV in the HBeAg-negative phase with HBV DNA above the 2,000 IU/mL threshold for treatment in HBeAg-negative patients. Tenofovir alafenamide (TAF, Vemlidy) 25 mg daily is initiated. Medicare Part D prior authorization is obtained.

The patient is also counseled about:

Family screening (his wife and three adult children are screened; his wife is also chronic HBV; one daughter is susceptible and is offered the IRA 2022-expanded HBV vaccine series; two other adult children are vaccinated and immune).
HCC surveillance every 6 months given his Asian male age >40 status (semiannual ultrasound + AFP).
Long-term/lifelong treatment expectation.
HBV transmission prevention.

The screening encounter cost-sharing was $0; downstream care was subject to standard Part B cost-sharing covered by his Medicare Supplement Plan G; TAF was covered under his Part D plan, and the IRA Part D $2,000 OOP cap effective 2025 limits his annual out-of-pocket on TAF.

Example 2: Rural Georgia Age 70 Sub-Saharan African Immigrant Female Universal Screening at FQHC

A 70-year-old woman living in Clarkston (DeKalb County, an Atlanta suburb with substantial refugee resettlement), enrolled in Original Medicare Part B and Georgia Medicaid as dual eligible, immigrated to the US from Ethiopia 12 years ago. She has not been previously screened for HBV. She receives primary care at a Clarkston Federally Qualified Health Center with refugee-focused services and multilingual staff.

The primary care provider orders HBV three-test panel screening (G0499) under the universal screening framework. The panel returns: HBsAg negative, anti-HBs negative, anti-HBc positive. This isolated anti-HBc pattern requires further evaluation. HBV DNA testing returns negative (undetectable). The pattern is consistent with past resolved HBV infection with waned anti-HBs titer.

The primary care provider counsels the patient that she has prior HBV infection that has resolved without current chronic infection. No HBV antiviral treatment is needed. She is informed that no further routine HBV screening is indicated unless new high-risk exposure occurs. She is offered hepatitis A vaccination (susceptible), which she accepts.

The screening cost-sharing is $0; the confirmatory HBV DNA test as a diagnostic test was subject to standard Part B cost-sharing, covered by Medicaid as her secondary payer.

Example 3: Cobb County Age 67 Female Newly Medicare-Eligible IRA-Expanded HBV Vaccination

A 67-year-old woman living in Cobb County, enrolled in Medicare Advantage (Wellstar Total Care HMO) and newly Medicare-eligible. She is in good health with no specific HBV risk factors. She received some childhood vaccinations but does not recall HBV vaccination (HBV vaccine was approved in 1981 and became routine for US infants in 1991; she was not in the childhood vaccination cohort). Her Wellstar primary care provider conducts an Initial Preventive Physical Examination ("Welcome to Medicare" visit) and addresses her vaccine needs.

The provider orders HBV three-test panel screening (G0499) under the universal screening framework, which returns: HBsAg negative, anti-HBs negative, anti-HBc negative. She is susceptible to HBV infection.

Under the IRA 2022 Section 11401 expansion, she is offered HBV vaccination with $0 cost-sharing. She elects to receive the Heplisav-B vaccine (2-dose schedule, 0 and 1 month) for faster completion. She receives the first dose at her IPPE visit and returns 1 month later for the second dose. Post-vaccination anti-HBs titer testing is not routinely required for healthy adults but is performed (showing protective titer 320 mIU/mL) given her interest.

The HBV vaccination cost-sharing is $0 under IRA 2022. Without the IRA expansion, she would have faced standard Part B cost-sharing as a non-high-risk beneficiary, which would have been approximately $35 to $50 per dose (20% of Medicare-approved vaccine and administration). The IRA expansion eliminated this barrier.

Example 4: DeKalb County HIV/HBV Coinfection Coordinated Treatment at Emory

A 72-year-old Korean American man living in DeKalb County, enrolled in Original Medicare Part B, has chronic HBV diagnosed at age 30 and chronic HIV diagnosed at age 50. He receives coordinated care between Emory Hepatology and the Emory Infectious Disease Center. His current antiretroviral therapy (ART) regimen includes tenofovir alafenamide / emtricitabine / bictegravir, which provides effective treatment for both his HIV and his HBV (tenofovir component active against both viruses).

His annual HBV monitoring includes HBV DNA quantification (undetectable on therapy), ALT (normal), FibroScan annually (F3 fibrosis stable), HCC surveillance ultrasound and AFP every 6 months. His HIV is also well-controlled with undetectable viral load and CD4 count above 700.

The case illustrates how Medicare Part D coverage of antiretroviral therapy provides simultaneous HBV antiviral coverage when tenofovir-containing regimens are used. Coordinated care between hepatology and infectious disease specialists optimizes management for HIV/HBV coinfection.

Example 5: Three-Test Panel Showing Past Resolved Infection at Piedmont Athens

A 65-year-old man living in Athens (Clarke County), enrolled in Original Medicare Part B, comes to a Piedmont Athens primary care practice for his Initial Preventive Physical Examination. He has no specific identified HBV risk factors. The primary care provider orders HBV three-test panel screening (G0499) under the universal screening framework.

The panel returns: HBsAg negative, anti-HBs positive (titer 240 mIU/mL), anti-HBc positive. This pattern indicates past resolved HBV infection with sustained natural immunity. The patient is surprised; he does not recall having had HBV. He may have had subclinical infection at some point in the past.

The primary care provider explains the result: he had HBV infection at some point in his life, his body cleared the infection, and he now has natural immunity. He does not have chronic HBV and does not require antiviral treatment. No further routine HBV screening is needed unless new high-risk exposure occurs. He does not need HBV vaccination because he is already immune. The screening cost-sharing is $0.

Example 6: HBV/HCV Coinfection Complex Coordination at Wellstar

A 70-year-old man living in Cobb County, enrolled in Medicare Advantage (Wellstar Total Care HMO), has a history of injection drug use during the 1970s and 1980s. He was recently screened for HCV (universal screening per NCD 210.13 expansion) with positive antibody and positive HCV RNA (chronic HCV genotype 1). He has not previously been screened for HBV. His Wellstar primary care provider orders HBV three-test panel screening (G0499).

The panel returns: HBsAg positive, anti-HBs negative, anti-HBc positive. He has chronic HBV in addition to chronic HCV. He is referred to Wellstar Hepatology for coordinated evaluation. Workup includes HBV DNA 8,000 IU/mL, HCV viral load 2 million IU/mL, FibroScan F4 (compensated cirrhosis), ALT 95 (elevated), HIV negative.

The hepatology team plans:

HBV antiviral therapy with tenofovir alafenamide initiated immediately (given cirrhosis and HBV/HCV coinfection requires HBV suppression alongside HCV treatment).
HCV DAA treatment with sofosbuvir/velpatasvir (Epclusa) 12 weeks initiated after HBV antiviral therapy is established.
Close monitoring during HCV treatment for HBV reactivation (potential complication when HCV is cleared in HBV-coinfected patients).
HCC surveillance every 6 months given cirrhosis (ultrasound + AFP).

The patient achieves HCV SVR (cure) at 12 weeks post-DAA treatment without HBV reactivation. He continues lifelong HBV antiviral therapy and ongoing HCC surveillance. The complex case illustrates the importance of universal HBV and HCV screening particularly in patients with shared risk factors.

Part 13: Frequently Asked Questions

What is the Medicare HBV screening benefit?

Medicare covers HBV screening for adult beneficiaries through CMS coverage decision under Section 1861(ddd) preventive services authority, effective September 28, 2016 for high-risk adults and expanded to universal adult screening for 2024 aligning with 2020 USPSTF Grade B recommendation.

Who is eligible for HBV screening?

Under the current 2024 universal alignment, all adult Medicare beneficiaries are eligible for HBV screening. Annual screening continues to apply for beneficiaries with ongoing high-risk exposure.

What does the HBV vaccine cost under Medicare?

$0 for all Medicare beneficiaries effective January 1, 2023, per the Inflation Reduction Act of 2022 (Public Law 117-169) Section 11401. This eliminated the high-risk-only limitation that had constrained access under the original OBRA 1984 framework.

What is the IRA 2022 Section 11401?

Section 11401 of the Inflation Reduction Act of 2022 expanded Medicare Part B coverage of vaccines aligned with ACIP recommendations to $0 cost-sharing for all beneficiaries effective January 1, 2023. This applied to HBV vaccine and other ACIP-recommended adult vaccines.

What is the HCPCS code for HBV screening?

HCPCS G0499 (hepatitis B screening with hepatitis B three-test panel: HBsAg, anti-HBs, anti-HBc).

What is the three-test panel?

The three tests are: HBsAg (current infection if positive), anti-HBs (immunity if positive), anti-HBc (current or past infection if positive). The combination of results distinguishes among susceptible, vaccine-induced immunity, past resolved infection with immunity, chronic infection, and other patterns.

What does HBsAg positive mean?

HBsAg positive indicates current HBV infection. Persistent HBsAg positivity for more than 6 months defines chronic HBV infection. New positive HBsAg may represent acute or early chronic infection.

What does anti-HBs positive mean?

Anti-HBs positive indicates immunity to HBV. This may be vaccine-induced immunity (with anti-HBc negative) or post-resolved infection immunity (with anti-HBc positive). Anti-HBs titer ≥10 mIU/mL is considered protective.

What does anti-HBc positive mean?

Anti-HBc positive indicates HBV exposure at some point — either past resolved infection or current infection. Anti-HBc does not result from vaccination.

Why are Asian Americans at elevated HBV risk?

HBV is endemic in many Asian countries with high vertical (mother-to-child) transmission rates. Many Asian American adults acquired chronic HBV at birth or in childhood and have lived with infection silently. Approximately 60 percent of US chronic HBV infections are in Asian Americans.

Why are African immigrants at elevated HBV risk?

Sub-Saharan Africa has high HBV endemic prevalence (5 to 10 percent or higher in many countries). Immigrants from these regions often have chronic HBV acquired in childhood.

What treatment is available for chronic HBV?

First-line treatments are tenofovir alafenamide (TAF, Vemlidy), tenofovir disoproxil fumarate (TDF, Viread), and entecavir (Baraclude). These nucleos(t)ide analogues suppress HBV replication but do not cure infection.

Is HBV curable?

Current HBV antivirals suppress but do not cure infection. HBsAg loss ("functional cure") is uncommon but does occur in some patients with sustained treatment. Research on HBV cure is active.

How long does HBV treatment last?

HBV treatment is typically long-term or lifelong because antivirals suppress but do not eradicate the virus. Treatment discontinuation typically results in viral rebound. Some patients with sustained HBsAg loss may achieve durable response off treatment.

What is HCC surveillance?

Hepatocellular carcinoma surveillance involves semiannual liver ultrasound (with or without alpha-fetoprotein testing) for patients at elevated HCC risk including Asian men age 40+, Asian women age 50+, African-born patients age 20+, cirrhotic patients, and others.

Does Medicare cover HBV vaccine?

Yes. Medicare Part B covers HBV vaccine under Section 1861(s)(10)(B). Effective January 1, 2023 per IRA 2022 Section 11401, coverage is universal for all Medicare beneficiaries with $0 cost-sharing.

What about HBV vaccination for beneficiaries who already had the vaccine?

Beneficiaries with documented prior vaccination and protective anti-HBs titer do not need revaccination. Anti-HBs titer testing can verify immunity. Beneficiaries with uncertain prior vaccination history may have their anti-HBs tested, and if non-protective, may receive a booster or revaccination series.

How does the HBV vaccine schedule work?

Standard three-dose HBV vaccines (Engerix-B, Recombivax HB) follow 0, 1, 6 month schedule. Heplisav-B (approved 2017) uses 2-dose schedule (0, 1 month). PreHevbrio uses 3-dose schedule.

Can pregnant women receive HBV screening and vaccination?

HBV screening is a standard component of prenatal care. HBV vaccination is safe in pregnancy and is recommended for unvaccinated pregnant women at risk.

What if I'm dually eligible for Medicare and Medicaid?

Dually eligible beneficiaries have Medicaid as secondary payer for Part B cost-sharing. For HBV screening and vaccination, cost-sharing is already $0 under the ACA Section 4104 waiver and IRA Section 11401. For downstream care, Medicaid coverage applies based on plan structure.

What about HBV in dialysis patients?

Long-term hemodialysis patients face elevated HBV risk. HBV screening, vaccination, and ongoing surveillance are part of comprehensive dialysis care. Medicare End-Stage Renal Disease coverage includes these services.

What is HBV reactivation?

HBV reactivation is the recrudescence of HBV replication in a patient with chronic or past resolved HBV, typically triggered by immunosuppression (chemotherapy, biologic therapy, organ transplantation). Pre-emptive HBV antiviral therapy is typically indicated.

Does Medicare Advantage cover HBV screening and vaccination?

Yes. Medicare Advantage plans must cover the HBV screening and vaccination benefits at least as comprehensively as Original Medicare. Cost-sharing is $0 for both per the ACA Section 4104 and IRA Section 11401 frameworks.

Where in Georgia can I get HBV screening and vaccination?

HBV screening is available at any primary care practice or Medicare-enrolled laboratory. HBV vaccination is available at any Medicare-enrolled provider including primary care practices, pharmacies, and community health centers. Major Georgia hepatology programs at Emory, Wellstar, Piedmont, and others provide downstream care for chronic HBV. FQHCs provide integrated services particularly for immigrant communities.

Where can I get help understanding my Medicare HBV screening and vaccine coverage?

Contact GeorgiaCares SHIP at 1-866-552-4464 for free, unbiased Medicare counseling. Call 1-800-MEDICARE or Palmetto GBA at 1-866-238-9650 for specific claim questions. The American Liver Foundation (1-800-465-4837) and Hepatitis B Foundation (215-489-4900) provide patient education and support.

Resources and Contacts

For questions about the Medicare HBV Screening and Vaccination benefits and HBV care in Georgia, the following resources can help:

Medicare: 1-800-MEDICARE (1-800-633-4227). General Medicare benefit questions.
Palmetto GBA Medicare Administrative Contractor for Georgia: 1-866-238-9650. HBV screening and vaccine claim adjudication.
Georgia DCH Medicaid Member Services: 1-866-211-0950. Medicaid eligibility for dually eligible beneficiaries.
GeorgiaCares SHIP: 1-866-552-4464. Free Medicare counseling including HBV screening and vaccine benefit navigation.
Medicare Rights Center: 1-800-333-4114. Beneficiary advocacy and education.
Atlanta Legal Aid Society: 404-377-0701. Free legal assistance metro Atlanta.
Georgia Legal Services Program: 1-800-498-9469. Free legal assistance outside metro Atlanta.
211 Georgia: 211. Social service navigation.
Eldercare Locator: 1-800-677-1116. Local Area Agency on Aging services.
Georgia Department of Public Health: 404-657-2700. Viral hepatitis surveillance and program.
American Liver Foundation: 1-800-465-4837. HBV patient education.
Hepatitis B Foundation: 215-489-4900. HBV-specific patient education and advocacy.
CDC-INFO: 1-800-232-4636. Hepatitis information.
Center for Pan Asian Community Services (CPACS): Asian American health services metro Atlanta.
Emory Hepatology: Atlanta academic hepatology and liver transplant.
Wellstar Hepatology: North and west Georgia network.
Piedmont Hepatology: Metro Atlanta and statewide network.
Acentra Health Beneficiary and Family Centered Care Quality Improvement Organization: 1-844-455-8708. Quality concerns and appeals.

The Medicare HBV screening and vaccination benefits, particularly with the IRA 2022 universal vaccine coverage expansion effective January 1, 2023, provide every Georgia Medicare beneficiary access to comprehensive HBV prevention and early detection. The 2024 universal adult screening alignment ensures that chronic HBV — particularly common in Asian American and African immigrant Medicare populations — is identified for linkage to treatment, family-based screening, and HCC surveillance. With universal vaccination available at $0 cost-sharing, prevention of new HBV infection is accessible to all beneficiaries.